The first prandial agonist of GLP-1 receptors: the efficiency and safety ot its using in clinical practice
AbstractThe paper discusses the prandial effects of the prandial GLP-1 receptor agonist exenatide: as a result of the effective elimination of the prandial hyperglycemia and the glycemia variability, reduction of the hypoglycemia risk without the weight gain. It was the advantage of the using of the prandial glycemia regulator exenatide as monotherapy so a combination with oral drugs and insulin resulting to the enhancement the glycemic and non-glycemic parameters.
Keywords:type 2 diabetes mellitus, postprandial hyperglycemia, incretins, exenatide
Endocrinology: News, Opinions, Training. 2015; (3): 58–66.